Lincoln Park Capital Fund logo

Lincoln Park Capital Fund

North America, Illinois, United States, Chicago

Description

Lincoln Park Capital Fund, LLC is a Chicago-based institutional investor specializing in providing flexible capital solutions to public and private companies. Established in 1995, the firm has built a reputation for its opportunistic investment approach, primarily focusing on growth-oriented small-cap and micro-cap companies across various sectors, including biotechnology, healthcare, technology, and consumer products. Unlike traditional venture capital firms that typically invest in early-stage private companies, Lincoln Park Capital's core expertise lies in navigating the public markets, offering a distinct financing alternative for companies seeking capital without the complexities of traditional debt or equity offerings.

The firm's primary investment vehicles include Private Investments in Public Equity (PIPEs), registered direct offerings, and equity line facilities. These structures allow companies to access capital on an as-needed basis, providing a flexible and often less dilutive alternative to conventional financing rounds. Lincoln Park Capital positions itself as a long-term financial partner, offering capital for purposes such as working capital, research and development, product commercialization, and strategic acquisitions. Their strategy is particularly appealing to companies that require ongoing access to capital to fund their growth initiatives and operational needs in a dynamic market environment.

Based on their publicly disclosed transactions, Lincoln Park Capital Fund typically commits substantial capital. For instance, observed equity line facilities and purchase agreements range significantly, with commitments as low as $10 million for certain common stock purchase agreements and extending up to $100 million for larger equity line facilities. These figures represent the maximum amount of capital a company can draw down under the agreement, reflecting Lincoln Park Capital's capacity to deploy significant funds. The firm's ability to tailor these agreements to the specific needs of each company underscores its flexible and partnership-oriented approach to investing.

Lincoln Park Capital's model emphasizes providing efficient and timely access to capital, enabling companies to focus on their core business objectives rather than protracted fundraising efforts. Their deep understanding of public market dynamics allows them to structure deals that align with the long-term growth strategies of their portfolio companies. As a consistent provider of capital, Lincoln Park Capital Fund plays a crucial role in supporting the growth and development of emerging public companies in the United States.

Investor Profile

Lincoln Park Capital Fund has backed more than 32 startups, with 1 new investments in the last 12 months alone. The firm has led 22 rounds, about 69% of its total and boasts 29 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Post Ipo Secondary, Private Equity rounds (top funding stages).
  • Majority of deals are located in United States, Canada, Denmark.
  • Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
  • Led 1 rounds in the past year.
  • Typical check size: $10M – $100M.

Stage Focus

  • Post Ipo Equity (91%)
  • Post Ipo Secondary (3%)
  • Private Equity (3%)
  • Seed (3%)

Country Focus

  • United States (88%)
  • Canada (9%)
  • Denmark (3%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical
  • Biopharma
  • Oncology
  • Cleantech
  • Wellness
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Lincoln Park Capital Fund frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 1
Abingworth
Europe, England, United Kingdom, London
Co-Investments: 1
Altium Capital
North America, New York, United States, New York
Co-Investments: 2
AC
North America, Connecticut, United States, Westport
Co-Investments: 1
DC
North America, Illinois, United States, Chicago
Co-Investments: 1
Sio Capital Management
North America, New York, United States, New York
Co-Investments: 2
Monashee Investment Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
Bain Capital Life Sciences
North America, Massachusetts, United States, Boston
Co-Investments: 1
Ikarian Capital
North America, Texas, United States, Dallas
Co-Investments: 1
D2
North America, Indiana, United States, Huntington
Co-Investments: 1

Which angels does Lincoln Park Capital Fund often collaborate with?

PM
North America, Massachusetts, United States, Cambridge
Shared Deals: 1

What are some of recent deals done by Lincoln Park Capital Fund?

Cingulate Therapeutics

Morristown, New Jersey, United States

Cingulate Therapeutics uses a unique combination of delivery technology and proven medications that creates an unmatched release profile.

BiotechnologyHealth CareMedical
Post Ipo EquityJul 21, 2025
Amount Raised: $25,000,000
Dare Bioscience

La Jolla, California, United States

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products.

BiopharmaBiotechnologyHealth Care
Post Ipo EquityOct 21, 2024
Amount Raised: $15,000,000
Meta Materials

Dartmouth, Nova Scotia, Canada

Meta Materials is a platform technology company that partners with OEMs across an expanding range of industries.

Advanced MaterialsArtificial Intelligence (AI)CleanTechInformation TechnologyNanotechnology
Post Ipo EquitySep 11, 2023
Amount Raised: $50,000,000
Cybin

Toronto, Ontario, Canada

Cybin is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions.

BiotechnologyHealth CareMental HealthPharmaceutical
Post Ipo EquityMay 30, 2023
Amount Raised: $30,146,837
Eterna Therapeutics

Cambridge, Massachusetts, United States

Eterna Therapeutics is a biopharmaceutical firm in the clinical stages that researches and develops innovative cytokine-based therapies.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Post Ipo EquityApr 11, 2023
Amount Raised: $10,000,000
Marker Therapeutics

Minneapolis, Minnesota, United States

Marker Therapeutics is a clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.

BiotechnologyTherapeutics
Post Ipo EquityDec 13, 2022
Amount Raised: $25,000,000
PaxMedica

Tarrytown, New York, United States

PaxMedica is a biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders.

BiotechnologyMedicalPharmaceutical
Post Ipo EquityNov 17, 2022
Amount Raised: $20,000,000
Kintara Therapeutics

Vancouver, British Columbia, Canada

Kintara Therapeutics is engaged in developing and commercializing therapies for the treatment of cancer patients.

BiotechnologyHealth CareMedical
Post Ipo EquityAug 3, 2022
Amount Raised: $20,000,000
Evaxion Biotech

Copenhagen, Hovedstaden, Denmark

Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.

Biotechnology
Post Ipo EquityJun 7, 2022
Amount Raised: $40,000,000
Aquestive Therapeutics

Warren, New Jersey, United States

Aquestive is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems.

Pharmaceutical
Post Ipo EquityApr 13, 2022
Amount Raised: $40,000,000